专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

151. 发明申请

US20190315685A1 OXYGEN SCAVENGING MOLECULES, ARTICLES CONTAINING SAME, AND METHODS OF THEIR USE 审中-公开
公开(公告)号：US20190315685A1
公开(公告)日：2019-10-17
申请号：US16189363
申请日：2018-11-13
申请人： Plastipak Packaging, Inc.
发明人： Girish Nilkanth Deshpande , Paul David Weipert , Michael W. Ensley
IPC分类号： C07D207/00 , C08K5/00 , C07D209/48 , C08K5/3417 , C08K5/098 , C07D471/04 , B65D81/26 , C07D209/46 , C08K5/3432 , B01J20/06 , B01J20/22 , B01J20/26 , B65D65/38
摘要： The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol --- represents a single or a double bond; and R1, R2, and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.

152. 发明授权

US10125096B2 Oxygen scavenging molecules, articles containing same, and methods of their use 有权
公开(公告)号：US10125096B2
公开(公告)日：2018-11-13
申请号：US15147532
申请日：2016-05-05
申请人： Plastipak Packaging, Inc.
发明人： Girish Nilkanth Deshpande , Paul David Weipert , Michael W. Ensley
IPC分类号： B65D81/24 , C07D207/00 , C08K5/00 , C07D209/46 , C07D209/48 , C07D471/04 , C08K5/098 , C08K5/3417 , B65D81/26 , B01J20/06 , B01J20/22 , B01J20/26 , B65D65/38 , C08K5/3432
摘要： The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol - - - - represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.

153. 发明授权

US09481647B2 Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) 有权
标题翻译： [R-（R *，R *）] - 2-（4-氟苯基）-β，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] -1H - 吡咯-1-庚酸钙盐（2:1）
公开(公告)号：US09481647B2
公开(公告)日：2016-11-01
申请号：US14924011
申请日：2015-10-27
申请人： Warner-Lambert Company LLC
发明人： Joseph Francis Krzyzaniak , Kevin Quackenbush
IPC分类号： C07D207/00 , C07D207/34
CPC分类号： C07D207/34
摘要： Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
摘要翻译： [R-（R *，R *）] -2-（4-氟苯基）-β，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] - 指定为XX型，XXI型，XXII型，XXIII型，XXIV型，XXV型，XXVI型，XXVII型，XXVIII型，XXX型和XXX型的1H-吡咯-1-庚酸半钙盐，其特征在于它们的X 描述了射线粉末衍射，固体NMR和/或拉曼光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症，高胆固醇血症，骨质疏松症，良性前列腺增生症（BPH ）和阿尔茨海默病。

154. 发明授权

US09416138B2 Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors 有权
标题翻译：用作MoGAT-2抑制剂的苄基磺酰胺化合物
公开(公告)号：US09416138B2
公开(公告)日：2016-08-16
申请号：US14438435
申请日：2013-10-30
申请人： Eli Lilly and Company
发明人： Francisco Javier Agejas-Chicharro , Nuria Diaz Buezo , Joseph Michael Gruber , Douglas Richard Stack
IPC分类号： C07D207/00 , C07D491/056 , C07D273/00 , C07D309/04 , C07D311/58 , C07D311/76 , C07D217/24 , C07D319/12 , C07D319/20 , C07D263/58 , C07D491/052 , C07D265/30 , C07D265/36 , C07D207/14 , C07D307/22 , C07D307/79 , C07D309/00 , C07D311/00 , C07D217/00 , C07D319/00 , C07D263/00 , C07D307/00 , C07D307/87
CPC分类号： C07D491/056 , C07D207/00 , C07D207/14 , C07D217/00 , C07D217/24 , C07D263/00 , C07D263/58 , C07D265/30 , C07D265/36 , C07D273/00 , C07D307/00 , C07D307/22 , C07D307/79 , C07D307/87 , C07D309/00 , C07D309/04 , C07D311/00 , C07D311/58 , C07D311/76 , C07D319/00 , C07D319/12 , C07D319/20 , C07D491/052
摘要： The present invention provides compounds of Formula I. Wherein R1, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the compounds.
摘要翻译：本发明提供式I化合物，其中R1，L和A如本文所述，或其药学盐，制备化合物的方法，以及使用该化合物治疗诸如高甘油三酯血症的病症的方法。

155. 发明授权

US09238648B2 Asymmetric synthesis method, related raw material and preparation method of (S,S)-2,8-diazabicyclo[4,3,0]nonane 有权
标题翻译：不对称合成方法，相关原料及（S，S）-2,8-二氮杂双环[4,3,0]壬烷的制备方法
公开(公告)号：US09238648B2
公开(公告)日：2016-01-19
申请号：US13977526
申请日：2012-09-20
申请人： SHANGHAI PUYI CHEMICAL TECHNOLOGY CO., LTD
发明人： Xiaobo Shentu , Yantao Qi , Lingshi Xie , Bo Wang
IPC分类号： C07D207/00 , C07D471/04 , C07D207/24 , C07D207/14 , C07D207/27
CPC分类号： C07D471/04 , C07D207/14 , C07D207/24 , C07D207/27 , Y02P20/55
摘要： The present invention relates to an asymmetric synthesis method of a chiral intermediate (S,S)-2,8-diazabicyclo[4,3,0]nonane (I) of moxifloxacin, wherein an imide or enamine compound is obtained by dehydration reaction of the pyrrolidine-3-ketone as shown in formula (II) and chiral amine(R)-1-phenylethylamine, followed by the reduction of the imide or enamine compound to obtain a compound of formula (III) or (IV) having the chiral structure of formula (I), and then a compound of formula (I) is obtained by intramolecular cyclization, and removal of the chiral auxiliary group and amino-protecting group. The present invention also relates to pyrrolidine-3-ketone as shown in formula (II) and a preparation method therefor, and in the formula (I), (II), (III), (IV), R is an amino-protecting group, especially C1-4 alkoxycarbonyl, benzyloxycarbonyl or benzyl which can be removed by hydrolysis or hydrogenation. Z═H2 or O; when Z═H2, Y is chlorine, bromine, iodine, methanesulfonate, tosylate, hydroxyl or hydroxyl with protection; and when Z═O, Y is OR1, and R1 is C1-4 alkyl.
摘要翻译：本发明涉及莫西沙星手性中间体（S，S）-2,8-二氮杂双环[4,3,0]壬烷（I）的不对称合成方法，其中酰亚胺或烯胺化合物是通过（II）所示的吡咯烷-3-酮和手性胺（R）-1-苯基乙胺，然后还原酰亚胺或烯胺化合物，得到具有手性的式（III）或（IV）的化合物式（I）的结构，然后通过分子内环化获得式（I）化合物，并除去手性辅助基团和氨基保护基。本发明还涉及式（II）所示的吡咯烷-3-酮及其制备方法，式（I），（II），（III），（IV）中R是氨基保护基基团，特别是可以通过水解或氢化除去的C 1-4烷氧基羰基，苄氧基羰基或苄基。 Z = H 2或O; 当Z = H 2时，Y为氯，溴，碘，甲磺酸酯，甲苯磺酸酯，羟基或羟基保护; 当Z = O时，Y为OR 1，R 1为C 1-4烷基。

156. 发明授权

US09221756B2 Pyrrole derivatives 有权
标题翻译：吡咯衍生物
公开(公告)号：US09221756B2
公开(公告)日：2015-12-29
申请号：US14360365
申请日：2012-12-05
申请人： University of Leicester
发明人： Peter William Andrew , Rana Lonnen , Fritz-Frieder Frickel , Simon Christopher Hirst , Mark William Davies , Daniel Hamza
IPC分类号： C07D207/00 , C07D207/36 , C07D401/04 , C07D401/12 , C07D403/04 , C07D407/04 , C07D413/04 , C07D417/04 , C07C229/18 , C07C237/06 , C07C229/42 , C07C237/20 , C07D207/38 , C07D401/14 , C07F9/572
CPC分类号： C07D207/36 , A61K31/402 , A61K31/4025 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/675 , A61K45/06 , C07C229/18 , C07C229/42 , C07C237/06 , C07C237/20 , C07D207/38 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D407/04 , C07D413/04 , C07D417/04 , C07F9/572
摘要： There are provided inter alia compounds of formula (I) wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.
摘要翻译：特别是提供式（I）化合物，其中R 1，R 2，R 3，R 4a和R 4b如说明书中所定义，以及它们在治疗中的用途，特别是在细菌（例如肺炎球菌）感染的治疗中。

157. 发明授权

US09221754B2 Crystalline forms of zofenopril calcium 有权
标题翻译：佐芬普利钙的结晶形式
公开(公告)号：US09221754B2
公开(公告)日：2015-12-29
申请号：US14478307
申请日：2014-09-05
申请人： Generics [UK] Limited
发明人： Vinayak Govind Gore , Priyesh Vijayakar , Ashok Pehere
IPC分类号： A01N43/36 , A61K31/40 , C07D207/00 , C07D207/16 , A61K31/401
CPC分类号： C07D207/16 , A61K31/401
摘要： The present invention relates to two novel crystalline forms of zofenopril calcium, to processes for their preparation and their use in pharmaceutical compositions.
摘要翻译：本发明涉及佐芬普利钙的两种新型结晶形式，其制备方法及其在药物组合物中的应用。

158. 发明授权

US09199932B2 Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) 有权
标题翻译： [R-（R *，R *）] -2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 1H-吡咯-1-庚酸钙盐（2:1）
公开(公告)号：US09199932B2
公开(公告)日：2015-12-01
申请号：US14520742
申请日：2014-10-22
申请人： Warner-Lambert Company LLC
发明人： Joseph Francis Krzyzaniak , Kevin Quackenbush
IPC分类号： C07D207/00 , C07D207/34
CPC分类号： C07D207/34
摘要： Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，β-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 表示XX型，XXI型，XXIV型，XXV型，XXVI型，XXVII型，XXVIII型，XXIX型和XXX型的1H-吡咯-1-庚酸半钙盐，其特征在于它们本发明描述了X射线粉末衍射，固体NMR和/或拉曼光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症，高胆固醇血症，骨质疏松症，良性前列腺增生症 BPH）和阿尔茨海默病。

159. 发明授权

US09099659B2 Organic electroluminescent element material, organic electroluminescent element, display device, and lighting device 有权
标题翻译：有机电致发光元件材料，有机电致发光元件，显示装置和照明装置
公开(公告)号：US09099659B2
公开(公告)日：2015-08-04
申请号：US13965909
申请日：2013-08-13
申请人： Konica Minolta, Inc.
发明人： Tomohiro Oshiyama , Eisaku Katoh , Noriko Yasukawa
IPC分类号： H01L51/54 , C07F15/00 , C09K11/06 , C07D207/00 , C07D403/04 , H01L51/00 , C07D231/12 , C07D233/58 , C07D401/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , H05B33/14 , H01L51/50
CPC分类号： H01L51/0085 , C07D231/12 , C07D233/58 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07F15/0033 , C07F15/0086 , C09K11/06 , C09K2211/1007 , C09K2211/1011 , C09K2211/1022 , C09K2211/1029 , C09K2211/1033 , C09K2211/1037 , C09K2211/1044 , C09K2211/1088 , C09K2211/1092 , C09K2211/185 , C09K2211/186 , H01L51/0042 , H01L51/0059 , H01L51/006 , H01L51/0069 , H01L51/0071 , H01L51/0081 , H01L51/0087 , H01L51/5012 , H01L51/5016 , H01L2251/308 , H05B33/14
摘要： This invention provides an organic EL element, which can control luminescence wavelength, exhibits high luminescence efficiency, and has a prolonged emission life, and a lighting equipment and a display device. They can be realized by an organic electroluminescent element material characterized by a metal complex having a structure represented by the following general formula (A) as a partial structure.
摘要翻译：本发明提供一种有机EL元件，其可以控制发光波长，显示高发光效率，并具有延长的发光寿命，以及照明设备和显示装置。它们可以通过特征在于具有由以下通式（A）表示的结构的金属络合物作为局部结构的有机电致发光元件材料来实现。

160. 发明授权

US09073852B2 Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid 有权
标题翻译：盐形式的[R-（R *，R *）] -2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 1H-吡咯-1-庚酸
公开(公告)号：US09073852B2
公开(公告)日：2015-07-07
申请号：US14340067
申请日：2014-07-24
申请人： Pfizer Inc.
发明人： Joseph Francis Krzyzaniak , Jason Albert Leonard
IPC分类号： C07D207/00 , C07D207/34 , C07D295/037 , C07C211/07 , C07C215/08 , C07C229/26 , C07D295/027
CPC分类号： C07D207/34 , C07C211/07 , C07C215/08 , C07C229/26 , C07D295/027 , C07D295/037
摘要： Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
摘要翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式